Amit Vora
Ophthalmology · Newton, NJNPI 1295999142
Payments from drug & device makers
Across 49 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$297
- Medtronic$224
- AbbVie$193
- Amgen$77
- Astellas Pharma US Inc$66
- Oyster Point Pharma, Inc.$45
- plus $215 from 10 others
What the payments were for
- Food & beverage$1,117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 9 | $297 |
| Medtronic | 7 | $224 |
| AbbVie | 8 | $193 |
| Amgen(2 entities) | 5 | $77 |
| Astellas Pharma US Inc | 4 | $66 |
| Oyster Point Pharma, Inc. | 3 | $45 |
| Sun Pharmaceutical Industries Inc. | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 2 | $31 |
| Bausch & Lomb Americas Inc. | 2 | $30 |
| Coopervision Inc. | 1 | $19 |
| Dompe US, Inc. | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
| Genmab U.S., Inc. | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,117 in reported general payments places this provider in the 40th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 83 | $113,043 |
| XiidraLifitegrast | 57 | $70,257 |
| LumiganBimatoprost | 98 | $46,264 |
| Cyclosporine | 58 | $29,869 |
| RocklatanNetarsudil Mesylat/Latanoprost | 37 | $23,007 |
| Prednisolone Acetate | 778 | $21,997 |
| CequaCyclosporine | 12 | $19,092 |
| Alphagan PBrimonidine Tartrate | 37 | $17,051 |
| VyzultaLatanoprostene Bunod | 29 | $13,970 |
| Doxycycline Hyclate | 53 | $12,155 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 70 | $11,835 |
| ProlensaBromfenac Sodium | 23 | $11,092 |
| RhopressaNetarsudil Mesylate | 29 | $10,777 |
| MoxifloxacinMoxifloxacin Hcl | 649 | $10,507 |
| Latanoprost | 920 | $10,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $193 | $184,604248 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $30 | $84,22786 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $36 | $19,09212 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $15 | $17,82449 claims |
| AlconSimbrinza | $297 | $7,16931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Newton
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.